BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  FDA Rejects Agile’s Contraceptive Patch Twirla For a Second Time

  Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla.

  December 22, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Arno Therapeutics Is Shuttering Its Doors

  Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma.

  December 22, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  North Carolina Sues Insys Accused of Bribing Doctors to Prescribe Powerful Opioid Spray

  North Carolina sued Insys on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

  December 22, 2017

   · 

  1 min read
• 

  BioMidwest

  Here Is The Future of Medtech in 2018

  “2018 will prove to be a landmark year for wearable technology as it continues to carve out its space within mainstream healthcare...”

  December 22, 2017

   · 

  1 min read
• 

  Policy

  Medical Device Tax Comes Back January 1

  For the first time in years, the medical device tax will take effect Jan. 1, after Congress left town without delivering on a long-promised delay or repeal.

  December 22, 2017

   · 

  1 min read
• 

  Deals

  Roche Does Last-Minute Christmas Shopping, Drops $1.7 Billion on San Diego Biotech

  Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego’s Ignyta.

  December 22, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biocon’s Biosimilar Arm May Raise $500M to Fund Clinical Development

  Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M.

  December 22, 2017

   · 

  1 min read
• 

  Biotech Bay

  3 Marijuana Biotech Stock Winners for 2018

  Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana.

  December 22, 2017

   · 

  1 min read
• 

  Drug Development

  Zhejiang Medicine Terminates Phase III Oncology Trial

  Zhejiang Medicine has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat AML due to a lack of efficacy.

  December 22, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  United Therapeutics to Pay $210M to Resolve U.S. Kickback Probe

  United Therapeutics Corporation will pay $210M to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients’ out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

  December 22, 2017

   · 

  1 min read